4DMedical USA Inc
$319.6K 64 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Medicines360
Medicines360 reported $321,350.01 across General Payments, Research, and Ownership to 58 physicians and teaching hospitals across 59 transactions.
- $321.4K
- All-tracks total
- 59
- Transactions
- 58
- Recipients
- −$199.5K
- General Payments vs PY2023
Medicines360 reported $321,350.01 across all CMS Open Payments tracks (General + Research + Ownership) to 58 physicians and teaching hospitals in Program Year 2024 - ranking #880 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $319,750.01, averaging $5.5K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer medicines360 Medicines360
$321.4K · #880/1,925 · 0.0% industry · PY2024
- TOT $321.4K
- RANK #880
- SHARE 0.0%
- TXN 59
- RCP 58
- CAT 6
- GEN $319.8K
- ΔGEN −$199.5K
- TOP1 46.2%
- PY 2024
Volume peers
Nearest volume peer: 4DMedical USA Inc ($319.6K)
Medicines360 sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Medicines360's CMS-reported General Payments decreased by $199.5K (−38.4%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: MEDICINES360PY2023: MEDICINES360PY2024: Medicines360. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $519,275.55
- PY2024
- $319,750.01
What the Data Shows for Medicines360
Rank #880 of 1,925 companies in CMS Open Payments for 2024 belongs to Medicines360, which reported $321,350.01 across 59 transactions to 58 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $5.4K per transaction and $5.5K per recipient.
Of the 6 general-payment categories charted below, "Consulting Fee" is the largest at $214.3K across 31 transactions, 67.0% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Medicines360 made 6 types of general payments. "Consulting Fee" is the largest category at $214.3K, 67.0% of General Payments.
Medicines360 reports 6 general-payment categories - the top three are Consulting Fee (67.0%), Royalty or License (31.3%), and Travel and Lodging (1.0%). The remaining 3 categories make up 0.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Medicines360 divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $214.3K | 31 | 67.0% |
| Royalty or License | $100.0K | 1 | 31.3% |
| Travel and Lodging | $3.2K | 15 | 1.0% |
| Food and Beverage | $861.10 | 9 | 0.3% |
| Grant | $750.00 | 1 | 0.2% |
| Compensation for Services Other Than Consulting | $595.00 | 1 | 0.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $314,860.08 (98.5%) of $319,750.01 in this company's General Payments records across 11 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Medicines360
The five named recipients with the highest reported General Payments from this company
- 1
Uc Davis Medical Center
$147,827.48 across 15 reported transactions
- 2
Matthew Reeves
$114,400.00 across 5 reported transactions
- 3
Elizabeth Onyemelukwe
$40,743.30 across 10 reported transactions
- 4
Jennifer Amico
$6,339.30 across 3 reported transactions
- 5
Laura Mckain
$5,550.00 across 3 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Medicines360's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Medicines360.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Medicines360.
Showing 6 of 1,924 companies with CMS-reported payment data.
Joint Jack Company LLC
$323.1K 0 recipients
Compare payment profiles
MedAlliance LLC
$323.3K 0 recipients
Compare payment profiles
Ortho Organizers, Inc.
$318.5K 1,210 recipients
Compare payment profiles
RefleXion Medical, Inc.
$318.2K 419 recipients
Compare payment profiles
DeGen Medical, Inc.
$324.9K 204 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.